Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-Week open-label trial

Dermatologic Surgery

Volumn 31, Issue 3, 2005, Pages 318-323

  Peris, Ketty ^a   Campione, Elena ^b   Micantonio, Tamara ^a   Marulli, Georgiana Clare ^b   Fargnoli, Maria Concetta ^a   Chimenti, Sergio ^b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EROSION; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; SIDE EFFECT; SKIN BURNING SENSATION; SKIN EDEMA; SKIN MANIFESTATION; SKIN PRURITUS; SKIN ULCER; SUPERFICIAL CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; MIDDLE AGED; SKIN TUMOR;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 18244384077     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042728-200503000-00012     Document Type: Article

References (40)

1. Thissen MRTM, Neumann MHA, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999;135:1177-83.
2. Telfer NR, Colver GB, Bowers PW. Guidelines for the management of basal cell carcinoma. Br J Dermatol 1999;141:415-23.
3. Sterry W, Stockfleth E. New treatment modalities for basal cell carcinoma. Recent Results Cancer Res 2002;160:259-68.
4. Peris K, Fargnoli MC, Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. N Engl J Med 1999;341:1767-8.
5. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998;134:25-30.
6. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999;41:1002-7.
7. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicentre 6-week dose-response trial. J Am Acad Dermatol 2001;44:807-13.
8. Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple keratoses. Arch Dermatol 2002;138:1498-502.
9. Persaud AN, Shamuelova E, Sherer D, et al. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. J Am Acad Dermatol 2002;47:553-6.
10. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol 2002;47:571-7.
11. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel-group, vehicle-controlled trials. J Am Acad Dermatol 2004;50:714-21.
12. Dendorfer M, Oppel T, Wollenberg A, Prinz JC. Topical treatment with imiquimod may induce regression of facial keratoacanthoma. Eur J Dermatol 2003;13:80-2.
13. Peris K, Micantonio T, Fargnoli MC. Successful treatment of keratoacanthoma and actinic keratoses with imiquimod 5% cream. Eur J Dermatol 2003;13:413-4.
14. Mackenzie-Wood A, Kossard S, de Launey J, et al. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001;44:462-70.
15. Gutzmer R, Kaspari M, Vogelbruch M, et al. Successful treatment of anogenital Bowen's disease with the immunomodulator imiquimod, and monitoring of therapy by DNA image cytometry. Br J Dermatol 2002;147:160-5.
16. Pehoushek J, Smith KJ. Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man. Arch Dermatol 2001;137:14-7.
17. Hengge UR, Schaller J. Successful treatment of invasive squamous cell carcinoma using topical imiquimod. Arch Dermatol 2004;140:404-6.
18. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 2000;143:843-5.
19. Powell AM, Russel-Jones R. Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy. J Am Acad Dermatol 2004;50:792-6.
20. Steinmann A, Funk JO, Schuler G, von der Driesch P. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000;43:555-6.
21. Wolf IH, Smolle J, Binder B, et al. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003;139:273-6.
22. Hesling C, D'Incan M, Mansard S, et al. In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. Br J Dermatol 2004;150:761-7.
23. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Comparison of dosing regimens. Arch Dermatol 2002;138:1165-71.
24. Cowen E, Mercurio MG, Gaspari A. An open case series of patients with basal cell carcinoma treated with topical 5% imiquimod cream. J Am Acad Dermatol 2002;47:S240-8.
25. Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002;147:1227-36.
26. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004;50:722-3.
27. Huber A, Huber JD, Skinner RB Jr, et al. Topical imiquimod treatment for nodular basal cell carcinoma: an open label series. Dermatol Surg 2004;30:429-30.
28. Stockfleth E, Ulrich C, Hauschild A, et al. Successful treatment of basal cell carcinoma in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. Eur J Dermatol 2002;12:569-72.
29. Micali G, De Pasquale R, Caltabiano R, et al. Topical imiquimod treatment of superficial and nodular basal cell carcinoma in patients affected by basal cell nevus sindrome: a preliminary report. J Dermatol Treat 2002;13:123-7.
30. Steiner A, Pehamberger H, Wolff K. In vivo epiluminescence microscopy of pigmented skin lesions. II. Diagnosis of small pigmented skin lesions and early detection of malignant melanoma. J Am Acad Dermatol 1987;17:584-91.
31. Peris K, Altobelli E, Ferrari A, et al. Interobserver agreement on dermoscopic features of pigmented basal cell carcinoma. Dermatol Surg 2002;28:1-3.
32. Dahl MV. Imiquimod: an immune response modifier. J Am Acad Dermatol 2000;43:S1-5.
33. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2002;43:S6-11.
34. Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000;114:135-41.
35. Lore K, Betts MR, Brenchley JM, et al. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J Immunol 2003;171:4320-8.
36. Schön M, Bong AB, Drewniok C, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003;95:1138-49.
37. Sullivan TP, Dearaujo T, Vincek V, Herman B. Evaluation of superficial basal cell carcinoma after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping. Dermatol Surg 2003;29:1181-6.
38. Chen TM, Rosen T, Orengo I. Treatment of a large superficial basal cell carcinoma with 5% imiquimod: a case report and review of the literature. Dermatol Surg 2002;28:344-6.
39. Dhres MM, Cook-Bolden F, Tanzi EL, Weinberg JM. Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature. Dermatol Surg 2002;28:427-9.
40. Kagy MK, Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg 2000;26:577-9.